The siRNA therapy cemdisiran achieved both primary and key secondary endpoints in the phase III NIMBLE trial for generalized myasthenia gravis, showing significant improvement in patient-reported and ...

Investigational treatment improves outcomes without complete complement blockade ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential ...

Accurate measurement of HMGB-1, neopterin and sIL-2R supports reliable assessment of immune activation across clinical and ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA). Geographic atrophy is characterized by progressive ...

Background: Ageing enhances chronic vascular inflammation, which promotes an increased risk of ischemic stroke, the third leading cause of death and disability worldwide. We have shown that complement ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled receptors in living cells actually respond to activating substances. The ...

Background Accumulating evidence has demonstrated that distinct tumour-promoting and tumour-restraining cancer-associated fibroblast (CAF) subtypes coexist in pancreatic ductal adenocarcinoma.